EUVIMEDEUVIMED entdecken
Open Access

Design, Synthesis, X‐Ray Crystallographic Characterization, Anticholinesterase and Antioxidant Evaluation, and Molecular Modeling of Novel Dispiroindene‐Pyrrolidine Derivatives as Multifunctional Anti‐Alzheimer Agents

Aisha A Alsfouk iD, Riham A El-Shiekh iD, Benson M Kariuki iD, Eman Sabry iD, Mohamed G Abouelenein iD, Asmaa Saleh iD, Mahmoud G A Saleh iD, Aladdin M Srour iD

Drug Development Research · 2026

DOI: 10.1002/ddr.70361 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, 2026. Verfasst von Aisha A Alsfouk und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia. Hauptthemen laut MEDLINE: Cholinesterase Inhibitors, Antioxidants, Pyrrolidines, Alzheimer Disease. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Princess Nourah Bint Abdulrahman University, Northern Border University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A novel series of 5‐chloro‐ N ‐alkyl‐1′,1″‐dimethyl‐4′‐aryldispiro[indene‐2,3′‐pyrrolidine‐2′,3″‐indoline]−1,2″(3 H )‐diones ( 4a–r ) was rationally designed and synthesized via a one‐pot multicomponent reaction of N ‐alkylated 5‐chloroisatin derivatives, 2‐(arylmethylidene)−2,3‐dihydro‐1 H ‐inden‐1‐ones ( 2a–i ), and sarcosine ( 3 ). To assess their potential therapeutic efficacy, the entire library of synthesized compounds was screened for its inhibitory profiles against both acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), where most derivatives exhibited moderate to potent cholinesterase inhibitory activity. Notably, derivatives 4b , 4f , and 4o emerged as the most effective dual inhibitors, displaying strong potent activity against AChE (IC 50 = 0.91 ± 0.02, 0.89 ± 0.01, and 0.74 ± 0.01 µM, respectively; donepezil IC 50 = 0.68 ± 0.005 µM) alongside significant BChE inhibition (IC 50 = 10.19 ± 0.16, 9.59 ± 0.08, and 9.11 ± 0.01 µM, respectively; donepezil IC 50 = 2.97 ± 0.01 µM). The structure of the most active derivatives ( 4b , 4f , and 4o ) was further confirmed by X‐ray crystallographic analysis. In addition, antioxidant evaluation of compounds 4b , 4f , and 4o demonstrated that derivative 4f possessed the most superior radical scavenging profile (IC 50 = 23.18 ± 0.33 µM), representing approximately a 5.5‐fold enhancement in potency relative to ascorbic acid (IC 50 = 128.20 ± 0.82 µM). Molecular docking studies revealed favorable binding interactions of the lead derivatives within the catalytic binding pockets of both AChE and BChE, with docking scores comparable to those of the standard inhibitor. Furthermore, in silico ADME profiling demonstrated promising pharmacokinetic behavior, characterized by robust gastrointestinal absorption and excellent predicted blood–brain barrier penetration, supporting the potential of these derivatives as promising multifunctional candidates for the development of anti‐Alzheimer agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cholinesterase InhibitorsAntioxidantsPyrrolidinesAlzheimer DiseaseDrug DesignCrystallography, X-RayAcetylcholinesteraseButyrylcholinesteraseAnimalsModels, MolecularStructure-Activity RelationshipHumansMolecular Docking Simulation

Stichwörter der Autor:innen

AChEAlzheimer'sX‐ray crystallographic analysisantioxidantdispiroindene‐pyrrolidinemolecular modeling

Substanzen

Cholinesterase InhibitorsAntioxidantsPyrrolidinesAcetylcholinesteraseButyrylcholinesterase

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia.
  • Department of Pharmacognosy, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
  • School of Chemistry, Cardiff University, Cardiff, UK.
  • National Research Centre, Chemical Industries Research Institute, Giza, Dokki, Egypt.
  • Chemistry Department, Faculty of Science, Menoufia University, Shebin El-Koom, Egypt.
  • Department of Chemistry, College of Science, Northern Border University, Arar, Saudi Arabia.

ORCID-Profile: Aisha A Alsfouk, Riham A El-Shiekh, Benson M Kariuki, Eman Sabry, Mohamed G Abouelenein, Asmaa Saleh, Mahmoud G A Saleh, Aladdin M Srour

Förderung

  • Princess Nourah Bint Abdulrahman University
  • Northern Border University

Zitieren

APA

Alsfouk, A. A., El-Shiekh, R. A., Kariuki, B. M., Sabry, E., Abouelenein, M. G., Saleh, A., Saleh, M. G. A., & Srour, A. M. (2026). Design, Synthesis, X‐Ray Crystallographic Characterization, Anticholinesterase and Antioxidant Evaluation, and Molecular Modeling of Novel Dispiroindene‐Pyrrolidine Derivatives as Multifunctional Anti‐Alzheimer Agents. Drug Development Research. https://doi.org/10.1002/ddr.70361

Vancouver

Alsfouk AA, El-Shiekh RA, Kariuki BM, Sabry E, Abouelenein MG, Saleh A, et al. Design, Synthesis, X‐Ray Crystallographic Characterization, Anticholinesterase and Antioxidant Evaluation, and Molecular Modeling of Novel Dispiroindene‐Pyrrolidine Derivatives as Multifunctional Anti‐Alzheimer Agents. Drug Development Research. 2026. doi:10.1002/ddr.70361

BibTeX
@article{Alsfouk2026,
  author = {Alsfouk, Aisha A and El-Shiekh, Riham A and Kariuki, Benson M and Sabry, Eman and Abouelenein, Mohamed G and Saleh, Asmaa and Saleh, Mahmoud G A and Srour, Aladdin M},
  title = {Design, Synthesis, X‐Ray Crystallographic Characterization, Anticholinesterase and Antioxidant Evaluation, and Molecular Modeling of Novel Dispiroindene‐Pyrrolidine Derivatives as Multifunctional Anti‐Alzheimer Agents},
  journal = {Drug Development Research},
  year = {2026},
  doi = {10.1002/ddr.70361}
}
Kostenlos starten →